Family History of Prostate and Breast Cancer Integrated with a Polygenic Risk Score Identifies Men at Highest Risk of Dying from Prostate Cancer Before Age 75 Years

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2022 Sep 14

PMID 36103261

Authors

Anna Plym

Yiwen Zhang

Konrad H Stopsack

Yon Ho Jee

Fredrik Wiklund

Adam S Kibel

Peter Kraft

Edward Giovannucci

Kathryn L Penney

Lorelei A Mucci

Affiliations

Soon will be listed here.

Abstract

Purpose: Family history of prostate cancer is one of the few universally accepted risk factors for prostate cancer. How much an assessment of inherited polygenic risk for prostate cancer adds to lifetime risk stratification beyond family history is unknown.

Experimental Design: We followed 10,120 men in the Health Professionals Follow-up Study with existing genotype data for risk of prostate cancer and prostate cancer-specific death. We assessed to what extent family history of prostate or breast cancer, combined with a validated polygenic risk score (PRS) including 269 prostate cancer risk variants, identifies men at risk of prostate cancer and prostate cancer death across the age span.

Results: During 20 years of follow-up, 1,915 prostate cancer and 166 fatal prostate cancer events were observed. Men in the top PRS quartile with a family history of prostate or breast cancer had the highest rate of both prostate cancer and prostate cancer-specific death. Compared with men at lowest genetic risk (bottom PRS quartile and no family history), the HR was 6.95 [95% confidence interval (CI), 5.57-8.66] for prostate cancer and 4.84 (95% CI, 2.59-9.03) for prostate cancer death. Men in the two upper PRS quartiles (50%-100%) or with a family history of prostate or breast cancer (61.8% of the population) accounted for 97.5% of prostate cancer deaths by age 75 years.

Conclusions: Our study shows that prostate cancer risk stratification on the basis of family history and inherited polygenic risk can identify men at highest risk of dying from prostate cancer before age 75 years.

Citing Articles

Co-modulation of a circular form of PCDH11Y during neuroendocrine differentiation of prostate cancer.

Pecoraro G, Leone I, Nuzzo S, Negueruela S, Smaldone G, Buono L Front Oncol. 2025; 15:1502405.

PMID: 40008007 PMC: 11850525. DOI: 10.3389/fonc.2025.1502405.

Oncological Safety of MRI-Informed Biopsy Decision-Making in Men With Suspected Prostate Cancer.

Hamm C, Asbach P, Pohlmann A, Schoots I, Kasivisvanathan V, Henkel T JAMA Oncol. 2024; 11(2):145-153.

PMID: 39666360 PMC: 11843366. DOI: 10.1001/jamaoncol.2024.5497.

Predictive value of polygenic risk score for prostate cancer incidence and prognosis in the Han Chinese.

Hung S, Chang L, Hsiao T, Wei C, Wang S, Li J Sci Rep. 2024; 14(1):20453.

PMID: 39227454 PMC: 11372043. DOI: 10.1038/s41598-024-71544-7.

Early Prostate Cancer Deaths Among Men With Higher vs Lower Genetic Risk.

Plym A, Zhang Y, Stopsack K, Ugalde-Morales E, Seibert T, Conti D JAMA Netw Open. 2024; 7(7):e2420034.

PMID: 38958976 PMC: 11222990. DOI: 10.1001/jamanetworkopen.2024.20034.

Clinical features of prostate cancer by polygenic risk score.

Spears C, Xu M, Shoben A, Dason S, Toland A, Byrne L Fam Cancer. 2024; 23(4):499-505.

PMID: 38619781 PMC: 11512885. DOI: 10.1007/s10689-024-00369-0.

References

Wolf A, Wender R, Etzioni R, Thompson I, DAmico A, Volk R . American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010; 60(2):70-98. DOI: 10.3322/caac.20066. View

Ewing C, Ray A, Lange E, Zuhlke K, Robbins C, Tembe W . Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med. 2012; 366(2):141-9. PMC: 3779870. DOI: 10.1056/NEJMoa1110000. View

Sabol R, Ledet E, Jaeger E, Hatton W, Moses M, Lankford A . Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients. Prostate. 2021; 81(7):427-432. DOI: 10.1002/pros.24120. View

Barnes D, Silvestri V, Leslie G, McGuffog L, Dennis J, Yang X . Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. J Natl Cancer Inst. 2021; 114(1):109-122. PMC: 8755508. DOI: 10.1093/jnci/djab147. View

Barber L, Gerke T, Markt S, Peisch S, Wilson K, Ahearn T . Family History of Breast or Prostate Cancer and Prostate Cancer Risk. Clin Cancer Res. 2018; 24(23):5910-5917. PMC: 6279573. DOI: 10.1158/1078-0432.CCR-18-0370. View

Kachuri L, Graff R, Smith-Byrne K, Meyers T, Rashkin S, Ziv E . Pan-cancer analysis demonstrates that integrating polygenic risk scores with modifiable risk factors improves risk prediction. Nat Commun. 2020; 11(1):6084. PMC: 7695829. DOI: 10.1038/s41467-020-19600-4. View

Conti D, Darst B, Moss L, Saunders E, Sheng X, Chou A . Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat Genet. 2021; 53(1):65-75. PMC: 8148035. DOI: 10.1038/s41588-020-00748-0. View

Nordstrom T, Discacciati A, Bergman M, Clements M, Aly M, Annerstedt M . Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial. Lancet Oncol. 2021; 22(9):1240-1249. DOI: 10.1016/S1470-2045(21)00348-X. View

Thomas 2nd J, Gerber L, Moreira D, Hamilton R, Banez L, Castro-Santamaria R . Prostate cancer risk in men with prostate and breast cancer family history: results from the REDUCE study (R1). J Intern Med. 2012; 272(1):85-92. PMC: 3576469. DOI: 10.1111/j.1365-2796.2011.02504.x. View

10.

Kenfield S, Batista J, Jahn J, Downer M, Van Blarigan E, Sesso H . Development and Application of a Lifestyle Score for Prevention of Lethal Prostate Cancer. J Natl Cancer Inst. 2015; 108(3). PMC: 5964905. DOI: 10.1093/jnci/djv329. View

11.

Hassanin E, May P, Aldisi R, Spier I, Forstner A, Nothen M . Breast and prostate cancer risk: The interplay of polygenic risk, rare pathogenic germline variants, and family history. Genet Med. 2021; 24(3):576-585. DOI: 10.1016/j.gim.2021.11.009. View

12.

Schumacher F, Olama A, Berndt S, Benlloch S, Ahmed M, Saunders E . Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2018; 50(7):928-936. PMC: 6568012. DOI: 10.1038/s41588-018-0142-8. View

13.

Kote-Jarai Z, Leongamornlert D, Saunders E, Tymrakiewicz M, Castro E, Mahmud N . BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer. 2011; 105(8):1230-4. PMC: 3208504. DOI: 10.1038/bjc.2011.383. View

14.

Shi Z, Platz E, Wei J, Na R, Fantus R, Wang C . Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis. Eur Urol. 2020; 79(3):419-426. DOI: 10.1016/j.eururo.2020.11.014. View

15.

Na R, Labbate C, Yu H, Shi Z, Fantus R, Wang C . Single-Nucleotide Polymorphism-Based Genetic Risk Score and Patient Age at Prostate Cancer Diagnosis. JAMA Netw Open. 2019; 2(12):e1918145. PMC: 6991229. DOI: 10.1001/jamanetworkopen.2019.18145. View

16.

Xu J, Labbate C, Isaacs W, Helfand B . Inherited risk assessment of prostate cancer: it takes three to do it right. Prostate Cancer Prostatic Dis. 2019; 23(1):59-61. DOI: 10.1038/s41391-019-0165-y. View

17.

Rimm E, Giovannucci E, Willett W, Colditz G, Ascherio A, Rosner B . Prospective study of alcohol consumption and risk of coronary disease in men. Lancet. 1991; 338(8765):464-8. DOI: 10.1016/0140-6736(91)90542-w. View

18.

Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A . Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. Am J Hum Genet. 2018; 104(1):21-34. PMC: 6323553. DOI: 10.1016/j.ajhg.2018.11.002. View

19.

Huynh-Le M, Karunamuni R, Fan C, Thompson W, Muir K, Lophatananon A . Common genetic and clinical risk factors: association with fatal prostate cancer in the Cohort of Swedish Men. Prostate Cancer Prostatic Dis. 2021; 24(3):845-851. PMC: 8387332. DOI: 10.1038/s41391-021-00341-4. View

20.

Graff R, Cavazos T, Thai K, Kachuri L, Rashkin S, Hoffman J . Cross-cancer evaluation of polygenic risk scores for 16 cancer types in two large cohorts. Nat Commun. 2021; 12(1):970. PMC: 7880989. DOI: 10.1038/s41467-021-21288-z. View